Olema Pharmaceuticals (OLMA) Interest & Investment Income (2020 - 2026)
Olema Pharmaceuticals (OLMA) reported Interest & Investment Income of $4.8 million for Q1 2026, up 5.57% year-over-year from $4.5 million in Q1 2025, and up 19.1% quarter-over-quarter from $4.0 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Interest & Investment Income (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Interest & Investment Income data on file, last reported at $4.8 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $4.8 million, up 5.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.5 million (up 18.93% YoY), and the FY2025 annual result was $16.2 million, up 27.93% from the prior year.
- Interest & Investment Income advanced to $4.8 million in Q1 2026 per OLMA's latest filing, from $4.0 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $4.8 million in Q1 2026 and troughed at $218000.0 in Q1 2022.
- A 5-year average of $2.6 million and a median of $3.1 million in 2024 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income surged 792.66% in 2022, then slipped 7.24% in 2024.
- A 5-year view of Interest & Investment Income shows it stood at $973000.0 in 2022, then surged by 264.95% to $3.6 million in 2023, then decreased by 7.24% to $3.3 million in 2024, then rose by 21.74% to $4.0 million in 2025, then gained by 19.1% to $4.8 million in 2026.
- Business Quant data shows OLMA's Interest & Investment Income at $4.8 million in Q1 2026, $4.0 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -14.79 Mn |
| 10 | Olema Pharmaceuticals | 1.01 Bn | 1.01 Bn | - | 4.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.78 Mn |
| Dec 31, 2025 | 4.01 Mn |
| Sep 30, 2025 | 3.65 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Mar 31, 2025 | 4.52 Mn |
| Dec 31, 2024 | 3.29 Mn |
| Sep 30, 2024 | 2.93 Mn |
| Jun 30, 2024 | 3.11 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Dec 31, 2023 | 3.55 Mn |
| Sep 30, 2023 | 1.92 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 973,000.00 |
| Sep 30, 2022 | 622,000.00 |
| Jun 30, 2022 | 415,000.00 |
| Mar 31, 2022 | 218,000.00 |
| Dec 31, 2021 | 109,000.00 |
| Sep 30, 2021 | 105,000.00 |
| Jun 30, 2021 | 117,000.00 |